These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15748956)

  • 21. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
    De Stefano N; Curtin F; Stubinski B; Blevins G; Drulovic J; Issard D; Shotekov P; Gasperini C;
    Mult Scler; 2010 Jul; 16(7):888-92. PubMed ID: 20200197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
    Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
    J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
    Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
    Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS; Rice GP; Alsop JC;
    Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA;
    Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.
    Bonavita S; Dinacci D; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Bresciamorra V; Orefice G; Paciello M; Coniglio G; Di Costanzo A; Valentino P; Patti F; Salemi G; Simone I; Tedeschi G
    Neurol Sci; 2006 Sep; 27 Suppl 5():S365-8. PubMed ID: 16998722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
    Wu X; Kuusisto H; Dastidar P; Huhtala H; Nikkari ST; Ukkonen M; Höyhtyä M; Elovaara I
    Acta Neurol Scand; 2007 Jul; 116(1):43-8. PubMed ID: 17587254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
    Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM; Peppler R; VanderBrug Medendorp S; Lehmann P; Alam J
    Ann Neurol; 1996 Oct; 40(4):618-27. PubMed ID: 8871582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.